secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001104659-23-060164
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Q1 net loss $5.1M; FDA sets ADCOM for NurOwn ALS BLA
--------------------------------------------------------------------

- Cash and equivalents $2.2M at March 31, 2023, down from $3.0M at Dec 31, 2022.
- Net loss of $5.1M ($0.14 per share) vs. $5.4M ($0.15) in Q1 2022.
- FDA to hold Advisory Committee meeting to review NurOwn BLA for ALS; PDUFA date to be set.
- Appointed Dr. Kirk Taylor as EVP and Chief Medical Officer in April 2023.
- R&D expenses $2.9M (up from $2.6M); G&A expenses $2.2M (down from $2.9M) year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923060164/0001104659-23-060164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923060164/tm2315779d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer